All samples·Sample analysis

Get your own pass — $199

radioligand therapy for prostate cancer OrganizationsJOHNS HOPKINS UNIVERSITY

JOHNS HOPKINS UNIVERSITY

Projects attributed to JOHNS HOPKINS UNIVERSITY within this analysis sample.

In This Analysis

Projects

6

NIH Funding

$9.0M

Projects(6)

Project	PI	Category	Funding
Imaging, Dosimetry and Radiobiology for α-particle Emitter Radiopharmaceutical Therapy 5P01CA272222-03	KIESS, ANA PONCE	Therapeutics	$5.7M
Targeting glutamine metabolism to enhance the efficacy of radiopharmaceutical therapy 5R01CA295705-02	RAY, SANGEETA	Therapeutics	$1.0M
Combination Radiopharmaceutical Therapy and External Beam Radiotherapy 5R01CA240779-06	HOBBS, ROBERT FRANCOIS	Therapeutics	$968K
Intracellular Self-Assembly of Theranostic Nanoparticles for Enhanced Imaging and Tumor Therapy 5R01EB030376-04	BULTE, JEFF W.	Therapeutics	$520K
Synthetic lethal metabolic drug combinations for castration-resistant prostate cancer 5K08CA273167-03	SENA, LAURA A.	Therapeutics	$438K
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer 5R01CA238284-05	LUO, JUN	Therapeutics	$356K

See JOHNS HOPKINS UNIVERSITY’s full platform profile

Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.